Clinical trials: Cancer: Solid Tumors
Metastatic Breast Cancer, Metastatic Solid Cancer
HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
This phase II study aims to confirm the diagnostic performance and accuracy of 68Ga-ABS011 PET/CT in determining the HER2 expression status, and to evaluate 68Ga-ABS011's ability to drive changes in therapeutic treatment.
- Trial name
- HERMIA (NCT06369831)
- Testing
- 68Ga-NOTA-ABSCINT-HER2 PET/CT
- Where
- 7 sites in Austria, Belgium
- Volunteers
- 60 people
- Sponsor
- Abscint NV/SA
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Bone Metastases, Unspecified Adult Solid Tumor, Protocol Specific
Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases
This phase I trial studies the side effects and best dose of hydroxychloroquine in treating patients with solid tumors undergoing radiation therapy for bone metastases.
- Trial name
- NCT01417403
- Testing
- hydroxychloroquine, radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054288
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Advanced Solid Tumors, Excluding Breast Cancer
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
This is a multi-center, open-label, single-sequence, crossover, drug-drug interaction (DDI) study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on the PK of dovitinib in patients with advanced solid tumors, excluding…
- Trial name
- CTKI258A2120 (NCT01700270)
- Testing
- dovitinib (TKI258), fluvoxamine
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
- Trial name
- eVOLVE-01 (NCT06448754)
- Testing
- Volrustomig, Carboplatin, Pemetrexed
- Where
- 63 sites in United States, China and 12 more
- Volunteers
- 194 people
- Sponsor
- AstraZeneca
Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT05605522
- Testing
- [225]-FPI-2059, [111In]-FPI-2058
- Where
- 8 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- 3B Pharmaceuticals GmbH
Advanced Solid Tumours, Carcinoma Non-small Cell Lung
First in Human Study of AZD9592 in Solid Tumors
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary…
- Conditions
- Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
- Trial name
- EGRET (NCT05647122)
- Testing
- AZD9592, Osimertinib, 5-Fluorouracil (5-FU)
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 190 people
- Sponsor
- AstraZeneca
Locally Advanced/Metastatic Solid Tumors
First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study
First-in-Human, Phase I, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of FL115 in patients with advanced solid tumors who have…
- Trial name
- NCT06130722
- Testing
- FL115
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Suzhou Forlong Biotechnology Co., Ltd
Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC)
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
- Trial name
- STAR (NCT06895031)
- Testing
- JYP0015
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Pediatric Cancer
Physical Activity in Pediatric Cancer (PAPEC)
The aim of this randomized controlled trial on Physical Activity and Pediatric Cancer (PAPEC) is to assess the impact of an exercise program intervention in pediatric cancer patients undergoing chemotherapy for solid tumors.
- Trial name
- PAPEC (NCT01645436)
- Testing
- exercise training
- Where
- Spain
- Volunteers
- 49 people
- Sponsor
- Universidad Europea de Madrid
Tumor, Solid
Varian ProBeam Proton Therapy System China Clinical Trial (Guangzhou)
This study is prospective, single-center, single-arm objective performance criteria. This trial will be conducted with a total of 47 subjects enrolled.
- Trial name
- NCT06338436
- Testing
- Proton Radiation Therapy System (ProBeam)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Varian, a Siemens Healthineers Company
Solid Tumor, Solid Tumor, Adult
Psychotherapy Intervention for Latinos With Advanced Cancer
The purpose of this study is to adapt a counseling intervention called Meaning Centered Psychotherapy to make it culturally relevant for Latinos. Cancer affects patients and their loved ones.
- Conditions
- Solid Tumor, Solid Tumor, Adult, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04015609
- Testing
- Meaning Centered Psychotherapy for Latinos, Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale, Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumors
SKB103 for Injection in Advanced Solid Tumors
This is a phase 1/2 clinical study to evaluate the safety and efficacy of SKB103 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.
- Trial name
- NCT07459998
- Testing
- SKB103 for injection monotherapy
- Where
- 2 sites in China
- Volunteers
- 277 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Solid Tumor
The Molecular Imaging Research of F-18 Labeled DX600 PET Probe
Angiotensin-converting enzyme 2 (ACE2) plays an important role in renin-angiotensin system (RAS) and has been reported to relate with cancer. Recently, it has also been proved as the key target for COVID-19 infection.
- Trial name
- NCT04542863
- Testing
- 18F-DX600 PET/CT
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking University Cancer Hospital & Institute
Advanced Solid Tumors
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase 1, open-label, dose-escalation and cohort expansion study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant…
- Trial name
- NCT07170787
- Testing
- IMM2510, IMM01
- Where
- China
- Volunteers
- 104 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Neoplasms
Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors
GSK1795091 is being developed for administration in combination with other immune system modulators for the treatment of cancers. The study will be conducted in two parts.
- Trial name
- NCT03447314
- Testing
- GSK1795091, GSK3174998, GSK3359609
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Metastatic Solid Tumors.
Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.
This is a phase II, multi-center (Israeli), open label, non-randomized trial for every patient with the specified tumors expressing c-kit or PDGFR.
- Trial name
- NCT00159016
- Testing
- Glivec
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Hadassah Medical Organization
Unspecified Adult Solid Tumor, Protocol Specific
LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy drugs may have different effects in patients with different degrees of kidney function.
- Trial name
- NCT00003706
- Testing
- pemetrexed disodium
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Solid Tumor
Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases
Apatinib and SHR-1210 are new drugs produced by jiangsu hengrui pharmaceutical co., LTD. Both are listed in China. The investigators want to design a trial to explore the efficacy and safety of Apatinib and SHR-1210 in patients…
- Trial name
- NCT04832204
- Testing
- Apatinib and Camrelizumab for Injection
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Beijing Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.